SCHEMBL2943261

SCHEMBL2943261

CC(=O)N(C(N)=O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
NPSR1 Q6W5P4 1/20 0.43
GAA P10253 1/20 0.42
ALOX5 P09917 1/20 0.41
APAF1 O14727 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 3/20 0.41
TSHR P16473 3/20 0.41
GLA P06280 1/20 0.41
KMT2A Q03164 4/20 0.40
MAPT P10636 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C19 P33261 2/20 0.39
POLB P06746 1/20 0.39
PARP1 P09874 1/20 0.39
RECQL P46063 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL764342 0.86 NPSR1 (0.50) NPSR1ALOX5NPC1ALDH1A1TSHR
SCHEMBL130476 0.86 CRHBP (0.56) CRHBPCRHR2NPSR1GAAAPAF1
SCHEMBL13760588 0.83 PLAU (0.41) CRHBPCRHR2NPSR1ALOX5APAF1
SCHEMBL27736663 0.83 ALDH1A1 (0.52) CRHBPCRHR2NPSR1GAAAPAF1
SCHEMBL4690665 0.82 CRHBP (0.53) CRHBPCRHR2NPSR1GAAAPAF1
SCHEMBL1409829 0.82 NPSR1 (0.46) CRHBPCRHR2NPSR1GAAALOX5
Hydrochloric Acid SCHEMBL11686695 0.80 CRHBP (0.51) CRHBPCRHR2NPSR1GAAAPAF1
SCHEMBL5933024 0.80 CRHBP (0.47) CRHBPCRHR2NPSR1GAAAPAF1
SCHEMBL27450892 0.79 GAA (0.35) CRHBPCRHR2GAA
SCHEMBL3073692 0.78 ALDH1A1 (0.45) NPSR1ALOX5NPC1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119386918-B Nitrogen-doped carbon nanotube domain-limited composite material, and preparation method and application thereof 中山大学 2025-04-08 CN claimed
CN-119386918-A Nitrogen-doped carbon nanotube domain-limited composite material, and preparation method and application thereof 中山大学 2025-02-07 CN claimed
US-9255285-B2 Fermentation medias and processes thereof BIOCON LIMITED (IN) 2016-02-09 US claimed
CN-101983242-B Fermentation medium containing urea nitrogen source and application of fermentation medium for producing recombinant protein BIOCON LTD. (IN) 2015-12-16 CN claimed
US-8927256-B2 Fermentation medias and processes thereof BIOCON LIMITED (IN) 2015-01-06 US claimed
US-20140141467-A1 Fermentation Medias and Processes Thereof BIOCON LIMITED (IN) 2014-05-22 US claimed
CN-103642843-A Fermentation media comprising urea-like nitrogen sources and its use for the production of secondary metabolits, enzymes and recombinant proteias BIOCON LTD 2014-03-19 CN claimed
EP-2565272-A2 Fermentation medias and processes thereof Biocon Limited (IN) 2013-03-06 EP claimed
CN-101983242-A Fermentation medium containing urea nitrogen source and its use for producing secondary metabolite, enzyme and recombinant protein BIOCON LTD 2011-03-02 CN claimed
US-20100317056-A1 FERMENTATION MEDIAS AND PROCESSES THEREOF BIOCON LIMITED (IN) 2010-12-16 US claimed
EP-2247737-A2 FERMENTATION MEDIAS AND PROCESSES THEREOF Biocon Limited (IN) 2010-11-10 EP claimed
WO-2009113099-A2 FERMENTATION MEDIAS AND PROCESSES THEREOF BIOCON LIMITED (IN) 2009-09-17 WO claimed
US-20080260842-A1 PERMEATION ENHANCING COMPOSITIONS FOR ANTICHOLINERGIC AGENTS ANTARES PHARMA, INC. 2008-10-23 US claimed
US-7425340-B2 Permeation enhancing compositions for anticholinergic agents ANTARES PHARMA IPL AG (CH) 2008-09-16 US claimed
EP-1742664-A1 PERMEATION ENHANCING COMPOSITIONS FOR ANTICHOLINERGIC AGENTS Antares Pharma IPL AG (CH) 2007-01-17 EP claimed
US-20050287194-A1 Permeation enhancing compositions for anticholinergic agents ANTARES PHARMA, INC. 2005-12-29 US claimed
WO-2005107812-A1 PERMEATION ENHANCING COMPOSITIONS FOR ANTICHOLINERGIC AGENTS ANTARES PHARMA IPL AG (CH) 2005-11-17 WO claimed
CN-119386918-B Nitrogen-doped carbon nanotube domain-limited composite material, and preparation method and application thereof 中山大学 2025-04-08 CN disclosed
EP-0351091-A2 Vulcanizable epoxy group-containing elastomer compositions SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1990-01-17 EP disclosed
EP-0257640-A2 Vulcanizable elastomer composition NIPPON ZEON CO., LTD. (JP) 1988-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080260842-A1 PERMEATION ENHANCING COMPOSITIONS FOR ANTICHOLINERGIC AGENTS SLC14A1, UTS2R, SLC18A3 CRHBP 1519/4885CRHR2 2392/4885NPSR1 1570/4885
US-20050287194-A1 Permeation enhancing compositions for anticholinergic agents SLC18A3, SLC14A1, UTS2R CRHBP 1353/4885CRHR2 2149/4885NPSR1 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.